首页> 外文期刊>Neuroscience: An International Journal under the Editorial Direction of IBRO >Production of beta-amyloid by primary human foetal mixed brain cell cultures and its modulation by exogenous soluble beta-amyloid.
【24h】

Production of beta-amyloid by primary human foetal mixed brain cell cultures and its modulation by exogenous soluble beta-amyloid.

机译:原代人胎儿混合脑细胞培养物产生β-淀粉样蛋白并通过外源可溶性β-淀粉样蛋白对其进行调节。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Previous studies on beta-amyloid production have been carried out using transfected cells and cell lines. We measured the 40 and 42 amino acid forms of beta-amyloid released into the culture medium by primary human foetal mixed brain cell aggregate culture over 3 months. In this model, neurones and supporting cells are maintained in serum-free defined medium. The secretion of significant amounts of beta-amyloid 40 and 42 was observed throughout culture for three separate cultures. Levels of beta-amyloid 40 and 42 closely followed the neuronal content of the cultures as estimated by cellular neurone-specific enolase. Addition of synthetic beta-amyloid 1-40 to the cultures for 1 week at 35 days in vitro resulted in a dose-related reduction in cellular neurone-specific enolase levels. Primary human aggregate brain cell cultures produced multimeric beta-amyloid, as determined by immunoassay. beta-Amyloid-treated cultures released diminishing amounts of multimeric beta-amyloid and contained increasing amounts of intracellular multimeric beta-amyloid with increasing exogenous beta-amyloid.These results suggest that release of multimeric beta-amyloid into the extracellular environment by human primary neurones can be affected by the presence of extracellular beta-amyloid. This has implications for Alzheimer's disease in that beta-amyloid released into the extracellular environment by dead/dying neurones could modulate beta-amyloid release by surrounding neurones, potentially causing amplification of toxicity. Moreover, intracellular beta-amyloid oligomer-dependent neurotoxicity may be a component of neurodegeneration in Alzheimer's disease, and other conditions with increased beta-amyloid synthesis, suggesting anti-amyloid therapies for Alzheimer's disease may have to target intracellular beta-amyloid.
机译:使用转染的细胞和细胞系已经进行了关于β-淀粉样蛋白产生的先前研究。我们测量了原代人胎儿混合脑细胞聚集培养物在3个月内释放到培养基中的40种和42种氨基酸形式的β-淀粉样蛋白。在该模型中,神经元和支持细胞保持在无血清的特定培养基中。在三个单独的培养物中,整个培养过程中观察到大量的β-淀粉样蛋白40和42的分泌。 β-淀粉样蛋白40和42的水平紧随细胞神经元特异性烯醇化酶估计的培养物中神经元含量。在体外35天将合成的β-淀粉样蛋白1-40添加到培养物中1周,导致细胞神经元特异性烯醇酶水平呈剂量相关性降低。通过免疫测定确定,原代人聚集的脑细胞培养物产生了多聚体β-淀粉样蛋白。经过β淀粉样蛋白处理的培养物释放的聚二聚体β淀粉样物质数量减少,并且细胞内的聚聚β淀粉样物质含量随着外源β淀粉样蛋白的增加而增加。受细胞外β-淀粉样蛋白的影响。这对阿尔茨海默氏病有影响,因为死/垂死的神经元释放到细胞外环境中的β-淀粉样蛋白可以调节周围神经元释放的β-淀粉样蛋白,从而可能导致毒性放大。此外,细胞内β-淀粉样蛋白寡聚物依赖性神经毒性可能是阿尔茨海默氏病神经变性的一个组成部分,而β-淀粉样蛋白合成增加的其他情况也表明,阿尔茨海默氏病的抗淀粉样蛋白疗法可能必须针对细胞内β-淀粉样蛋白。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号